• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合突变与克隆性分析支持甲状腺乳头状癌存在肿瘤内异质性。

Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer.

作者信息

Muzza Marina, Pogliaghi Gabriele, Persani Luca, Fugazzola Laura, Colombo Carla

机构信息

Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano IRCCS, 20095 Milan, Italy.

Division of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, 20095 Milan, Italy.

出版信息

J Clin Med. 2021 Jun 16;10(12):2645. doi: 10.3390/jcm10122645.

DOI:10.3390/jcm10122645
PMID:34208446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8234519/
Abstract

Despite its potential clinical impact, intra-tumor genetic heterogeneity (ITH) has been scantly investigated in papillary thyroid cancer (PTC). We studied ITH in PTC by combining, for the first time, data derived from the evaluation of the normalized allelic frequencies (NAF) of the mutation/s, using a customized MassARRAY panel, and those obtained by the HUMARA clonality assay. Among tumors with a single mutation, 80% of cases with NAF 50 ± 5% were clonal, consistent with the presence of a single mutated clone, while 20% of cases showed a polyclonal pattern, suggesting the presence of the same mutation in two or more clones. Differently, all cases with NAF < 45% were polyclonal. Among tumors with double mutation, cases with both mutations showing NAF 50 ± 5% were monoclonal, consistent with the presence of a single clone harboring both mutations. On the other hand, all cases with double mutation at NAF < 45% were polyclonal, indicating the presence of two clones with different mutations. Finally, no significant differences in the clinico-pathological characteristics were found between monoclonal and polyclonal tumors. In conclusion, the present study adds insights into the concept of ITH in PTC, which warrants attention because the occurrence of this phenomenon is likely to affect the response to targeted drugs.

摘要

尽管具有潜在的临床影响,但甲状腺乳头状癌(PTC)中的肿瘤内基因异质性(ITH)却鲜有研究。我们首次通过结合使用定制的MassARRAY检测板评估突变的标准化等位基因频率(NAF)所获得的数据以及通过HUMARA克隆性检测获得的数据,对PTC中的ITH进行了研究。在仅有一个突变的肿瘤中,NAF为50±5%的病例中有80%是克隆性的,这与单一突变克隆的存在一致,而20%的病例表现出多克隆模式,表明在两个或更多克隆中存在相同的突变。不同的是,所有NAF<45%的病例都是多克隆的。在有两个突变的肿瘤中,两个突变的NAF均为50±5%的病例是单克隆的,这与存在一个同时携带两个突变的克隆一致。另一方面,所有NAF<45%的双突变病例都是多克隆的,表明存在两个具有不同突变的克隆。最后,单克隆和多克隆肿瘤在临床病理特征上未发现显著差异。总之,本研究为PTC中ITH的概念提供了新的见解,这种现象的发生可能会影响对靶向药物的反应,因此值得关注。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bdb/8234519/1315dc8e7da8/jcm-10-02645-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bdb/8234519/d5be7a5fb49d/jcm-10-02645-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bdb/8234519/1315dc8e7da8/jcm-10-02645-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bdb/8234519/d5be7a5fb49d/jcm-10-02645-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bdb/8234519/1315dc8e7da8/jcm-10-02645-g002.jpg

相似文献

1
Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer.联合突变与克隆性分析支持甲状腺乳头状癌存在肿瘤内异质性。
J Clin Med. 2021 Jun 16;10(12):2645. doi: 10.3390/jcm10122645.
2
Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.基因突变密度和异质性对甲状腺乳头状癌临床特征和缓解概率的影响。
Thyroid. 2019 Feb;29(2):237-251. doi: 10.1089/thy.2018.0339. Epub 2019 Jan 16.
3
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance.甲状腺乳头状癌的瘤内遗传异质性:发生情况及临床意义
Cancers (Basel). 2020 Feb 7;12(2):383. doi: 10.3390/cancers12020383.
4
Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma.甲状腺乳头状癌不同病理阶段瘤内异质性的演变
Cancer Cell Int. 2022 Aug 22;22(1):263. doi: 10.1186/s12935-022-02680-1.
5
Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.多中心性多发性甲状腺乳头状癌——HUMARA和BRAF突变分析
Cancer Med. 2015 Aug;4(8):1272-80. doi: 10.1002/cam4.466. Epub 2015 Apr 17.
6
The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.BRAF(V600E) 的原发性发生是甲状腺乳头状癌中罕见的克隆事件。
J Clin Endocrinol Metab. 2012 Feb;97(2):517-24. doi: 10.1210/jc.2011-0618. Epub 2011 Dec 14.
7
Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone.大多数多灶性乳头状甲状腺癌在初始肿瘤克隆发生腺内播散后,通过亚克隆进化获得遗传和形态学多样性。
J Pathol. 2008 Jun;215(2):145-54. doi: 10.1002/path.2342.
8
Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas.胰腺导管内乳头状黏液性肿瘤的克隆性与场癌化
Cancer. 2001 Oct 1;92(7):1807-17. doi: 10.1002/1097-0142(20011001)92:7<1807::aid-cncr1697>3.0.co;2-0.
9
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.BRAF突变的异质性分布支持多灶性乳头状甲状腺癌中不同肿瘤灶的独立克隆起源。
J Clin Endocrinol Metab. 2007 Sep;92(9):3511-6. doi: 10.1210/jc.2007-0594. Epub 2007 May 29.
10
Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles.利用基因图谱对多灶性乳头状甲状腺癌进行克隆性分析。
J Pathol. 2016 May;239(1):72-83. doi: 10.1002/path.4696. Epub 2016 Apr 1.

引用本文的文献

1
Female-bias in systemic lupus erythematosus: How much is the X chromosome to blame?红斑狼疮:女性为何更易患病?X 染色体难逃其咎?
Biol Sex Differ. 2024 Oct 7;15(1):76. doi: 10.1186/s13293-024-00650-y.
2
PPARγ Targets-Derived Diagnostic and Prognostic Index for Papillary Thyroid Cancer.基于PPARγ靶点的甲状腺乳头状癌诊断和预后指标
Cancers (Basel). 2021 Oct 12;13(20):5110. doi: 10.3390/cancers13205110.

本文引用的文献

1
The clonal origin of multifocal papillary thyroid cancer: intrathyroidal spread or independent tumors?多灶性甲状腺乳头状癌的克隆起源:甲状腺内播散还是独立肿瘤?
Minerva Endocrinol (Torino). 2021 Mar;46(1):35-44. doi: 10.23736/S2724-6507.20.03302-7. Epub 2020 Oct 12.
2
Acquired Secondary RAS Mutation in BRAF-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.接受 BRAF 抑制剂治疗的 BRAF 突变型甲状腺癌患者中获得性继发性 RAS 突变。
Thyroid. 2020 Sep;30(9):1288-1296. doi: 10.1089/thy.2019.0514. Epub 2020 May 7.
3
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance.
甲状腺乳头状癌的瘤内遗传异质性:发生情况及临床意义
Cancers (Basel). 2020 Feb 7;12(2):383. doi: 10.3390/cancers12020383.
4
Dedifferentiation patterns in DTC: is PDTC an intermediate state between DTC and ATC?分化型甲状腺癌中的去分化模式:侵袭性包裹性滤泡性甲状腺癌是分化型甲状腺癌和未分化甲状腺癌之间的中间状态吗?
Int J Clin Exp Pathol. 2019 Jan 1;12(1):267-274. eCollection 2019.
5
Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer.甲状腺乳头状癌亚克隆突变的演变及其影响。
Am J Hum Genet. 2019 Nov 7;105(5):959-973. doi: 10.1016/j.ajhg.2019.09.026. Epub 2019 Oct 24.
6
Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer.配对的原发性和转移性甲状腺乳头状癌的全外显子组测序。
Thyroid. 2020 Jan;30(1):42-56. doi: 10.1089/thy.2019.0052. Epub 2019 Dec 4.
7
Early evolutionary divergence between papillary and anaplastic thyroid cancers.乳头状甲状腺癌和间变性甲状腺癌之间的早期进化差异。
Ann Oncol. 2019 Nov 1;30(11):1843. doi: 10.1093/annonc/mdz216.
8
KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.KRAS G12V 突变在甲状腺乳头状癌对联合 BRAF 和 MEK 抑制获得性耐药中的作用。
J Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.
9
Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator.基于靶向深度测序的肿瘤内异质性推断作为一种预后指标。
Sci Rep. 2019 Mar 14;9(1):4542. doi: 10.1038/s41598-019-41098-0.
10
Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.基因突变密度和异质性对甲状腺乳头状癌临床特征和缓解概率的影响。
Thyroid. 2019 Feb;29(2):237-251. doi: 10.1089/thy.2018.0339. Epub 2019 Jan 16.